\n–Initial Phase 1 dose-escalation data for SEA-TGT monotherapy in advanced malignancies to be disclosed –<\/i><\/strong><\/p>\n \n–Preclinical data and discovery research underscore Seagen\u2019s mission to innovate through next-generation ADC technologies –<\/i><\/strong><\/p>\n BOTHELL, Wash.–(BUSINESS WIRE<\/a>)–Seagen Inc.<\/a> (Nasdaq: SGEN) today announced the presentation of 17 abstracts featuring new clinical and preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando from April 14-19, 2023. The broad range of data being presented at this year\u2019s meeting includes research from Seagen\u2019s approved medicines, as well as data from early-stage clinical, preclinical, and discovery research programs.\n<\/p>\n \n\u201cSeagen\u2019s robust presence at AACR this year, highlighting progress across our diverse pipeline, underscores our commitment to improving and extending the lives of people living with cancer,\u201d said Roger Dansey, M.D., President of Research and Development and Chief Medical Officer at Seagen. \u201cAs a pioneer in antibody-drug conjugates, we strive to optimize and expand the potential of our core technology, while also progressing innovative, targeted cancer approaches.\u201d\n<\/p>\n \nHighlights include an interim analysis from the innovaTV 207 Phase 2 study of tisotumab vedotin (TV) given every 2 weeks in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have progressed after prior platinum combination, immunotherapy, and targeted therapy, if eligible. TV, which is being developed in partnership with Genmab, is a tissue factor (TF)-directed antibody-drug conjugate (ADC). The innovaTV 207 study is currently ongoing and evaluating alternative dosing regimens of TV across multiple advanced solid tumors.\n<\/p>\n \nOther notable clinical data include initial results from a Phase 1 dose-escalation study of SEA-TGT monotherapy in patients with advanced malignancies. SEA-TGT is a novel investigational nonfucosylated human IgG1 antibody directed against TIGIT, an inhibitory immune checkpoint receptor that has emerged as a clinically relevant immuno-oncology target. SEA-TGT continues to be evaluated both as monotherapy and in combination with an anti-PD1 agent.\n<\/p>\n \nSeagen will also present new preclinical findings on the antitumor activity of disitamab vedotin, an ADC that targets cancers expressing HER2, as a monotherapy and in combination with tucatinib in breast and gastric cancer models, and on SGN-B6A, a wholly-owned, first-in-class vedotin ADC that targets integrin beta-6, which is highly expressed in a range of solid tumors.\n<\/p>\n \nSeagen and Sanofi will also unveil the first preclinical data from a novel topoisomerase I inhibitor ADC targeting CEACAM5, showing potent antitumor activity in patient-derived colorectal cancer models. These are the first data disclosed from the companies\u2019 2022 collaboration to develop and commercialize multiple novel ADCs.\n<\/p>\n \nAdditional preclinical data disclosures are planned, highlighting vedotin programs and novel ADC and tumor targeting technologies, including payloads with immune stimulatory properties.\n<\/p>\n Details of Seagen Presentations at AACR Annual Meeting 2023<\/b><\/p>\n Abstract Title<\/b><\/p>\n<\/td>\n Abstract #<\/b><\/p>\n<\/td>\n Presentation Time<\/b><\/p>\n<\/td>\n Lead Author<\/b><\/p>\n<\/td>\n<\/tr>\n ADCETRIS\u00ae<\/sup> (brentuximab vedotin)<\/b><\/p>\n<\/td>\n<\/tr>\n \nCD30 is a marker of activated effector regulatory T cells in solid tumors providing clinical rationale for the combination of brentuximab vedotin and PD-1 inhibitors\n<\/p>\n<\/td>\n \n3253\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nClinical Research Excluding Trials \/ Combination Immunotherapies 1\n<\/p>\n \nMon., April 17\n<\/p>\n \n1:30 – 5:00 p.m. ET\n<\/p>\n<\/td>\n \nB. Grogan\n<\/p>\n<\/td>\n<\/tr>\n \nExposure-response and age subgroup analyses to support body-weight (BW) dosing of brentuximab vedotin (BV) in newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults (aged 2-21 years [y]): A randomized Children\u2019s Oncology Group phase 3 trial (AHOD1331)\n<\/p>\n<\/td>\n \n6737\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nClinical Research Excluding Trials \/ Preclinical Therapies and Clinical Observations in Pediatric Oncology\n<\/p>\n \nWed., April 19\n<\/p>\n \n9:00 a.m. – 12:30 p.m. ET\n<\/p>\n<\/td>\n \nZ. Zhang\n<\/p>\n<\/td>\n<\/tr>\n PADCEV\u00ae<\/sup> (enfortumab vedotin)<\/b><\/p>\n<\/td>\n<\/tr>\n \nEnfortumab vedotin, a Nectin-4-directed antibody-drug conjugate, demonstrates compelling antitumor activity in non-muscle invasive bladder cancer models and accurately predicts minimal systemic exposure when administered by intravesical instillation in patients\n<\/p>\n<\/td>\n \nLB246\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nLate-Breaking Research: Experimental and Molecular Therapeutics 2\n<\/p>\n \nTues., April 18\n<\/p>\n \n1:30 – 5:00 p.m. ET\n<\/p>\n<\/td>\n \nD. Olson\n<\/p>\n<\/td>\n<\/tr>\n TIDVAK\u00ae<\/sup> (tisotumab vedotin)<\/b><\/p>\n<\/td>\n<\/tr>\n \nTisotumab vedotin (TV) in squamous cell carcinoma of head and neck (SCCHN): interim analysis from innovaTV 207\n<\/p>\n<\/td>\n \nCT164\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nPhase II Clinical Trials 1\n<\/p>\n \nMon., April 17\n<\/p>\n \n1:30 – 5:00 p.m. ET\n<\/p>\n<\/td>\n \nB. Cirauqui\n<\/p>\n<\/td>\n<\/tr>\n TUKYSA\u00ae<\/sup> (tucatinib)<\/b><\/p>\n<\/td>\n<\/tr>\n \nPhase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial-in-progress)\n<\/p>\n<\/td>\n \nCT065\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nPhase II and Phase III Clinical Trials in Progress\n<\/p>\n \nMon., April 17\n<\/p>\n \n9:00 a.m. – 12:30 p.m. ET\n<\/p>\n<\/td>\n \nE. Hamilton\n<\/p>\n<\/td>\n<\/tr>\n \nTucatinib does not alter oxaliplatin PK or associated renal function: An OCT2\/MATE transport inhibition study\n<\/p>\n<\/td>\n \n5060\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nExperimental and Molecular Therapeutics – Theranostics and Radionuclides \/ Pharmacologic Approaches\n<\/p>\n \nTues., April 18\n<\/p>\n \n1:30 – 5:00 p.m. ET\n<\/p>\n<\/td>\n \nA. Topletz-Erickson\n<\/p>\n<\/td>\n<\/tr>\n Disitamab Vedotin<\/b><\/p>\n<\/td>\n<\/tr>\n \nDisitamab vedotin, an investigational HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical cancer models\n<\/p>\n<\/td>\n \n560\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nExperimental and Molecular Therapeutics \/ Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1\n<\/p>\n \nSun., April 16\n<\/p>\n \n1:30 – 5:00 p.m. ET\n<\/p>\n<\/td>\n \nK. Willis\n<\/p>\n<\/td>\n<\/tr>\n Early-Stage Programs<\/b><\/p>\n<\/td>\n<\/tr>\n \nSGN-BB228, a CD228-directed costimulatory antibody anticalin bispecific provides potent and conditional 4-1BB costimulation to T cells in vivo and in an in vitro model of T-cell exhaustion\n<\/p>\n \n\u00a0\n<\/p>\n<\/td>\n \n5676\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nClinical Research Excluding Trials \/ Therapeutic Antibodies, Including Engineered Antibodies\n<\/p>\n \nTues., April 18\n<\/p>\n \n1:30 – 5:00 p.m. ET\n<\/p>\n<\/td>\n \nB. Updegraff\n<\/p>\n<\/td>\n<\/tr>\n \nSGN-B6A induces immunogenic cell death as an additional mechanism of action\n<\/p>\n<\/td>\n \n1522\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nExperimental and Molecular Therapeutics \/ Antibody-Drug Conjugates\n<\/p>\n \nMon., April 17\n<\/p>\n \n9:00 a.m. – 12:30 p.m. ET\n<\/p>\n<\/td>\n \nV. Trang\n<\/p>\n<\/td>\n<\/tr>\n \nGeneration of an antibody-drug conjugate-optimized TLR7\/8 agonist payload\n<\/p>\n<\/td>\n \n1542\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nExperimental and Molecular Therapeutics \/ Antibody-Drug Conjugates\n<\/p>\n \nMon., April 17\n<\/p>\n \n9:00 a.m. – 12:30 p.m. ET\n<\/p>\n<\/td>\n \nK.P. Wang\n<\/p>\n<\/td>\n<\/tr>\n \nPhase 1 dose-escalation study of SEA-TGT monotherapy in patients with advanced malignancies\n<\/p>\n<\/td>\n \nCT265\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nPhase I Clinical Trials 2\n<\/p>\n \nTues., April 18\n<\/p>\n \n1:30 – 5:00 p.m. ET\n<\/p>\n<\/td>\n \nE. Garralda Cabanas\n<\/p>\n<\/td>\n<\/tr>\n \nUsing a clinical utility index (CUI) to determine the optimal biological dose of a nonfucosylated anti-TIGIT antibody: A proposed alternative to maximum tolerated dose (MTD)\n<\/p>\n<\/td>\n \n5668\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nClinical Research Excluding Trials \/ Therapeutic Antibodies, Including Engineered Antibodies\n<\/p>\n \nTues., April 18\n<\/p>\n \n1:30 – 5:00 p.m. ET\n<\/p>\n<\/td>\n \nG. Patilea-Vrana\n<\/p>\n<\/td>\n<\/tr>\n \nA preclinical model of acquired anti-PD-1 resistance is responsive to SEA-TGT, an effector-function enhanced anti-TIGIT monoclonal antibody\n<\/p>\n<\/td>\n \n6361\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nImmunology \/ Immune Checkpoints\n<\/p>\n \nWed., April 19\n<\/p>\n \n9:00 a.m. – 12:30 p.m. ET\n<\/p>\n<\/td>\n \nD. Gruber\n<\/p>\n<\/td>\n<\/tr>\n \nA novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5 has potent antitumor activity in colorectal cancer models\n<\/p>\n<\/td>\n \n4890\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nExperimental and Molecular Therapeutics \/ Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment\n<\/p>\n \nTues., April 18\n<\/p>\n \n1:30 – 5:00 p.m. ET\n<\/p>\n<\/td>\n \nY. Baudat\n<\/p>\n<\/td>\n<\/tr>\n Discovery Research<\/b><\/p>\n<\/td>\n<\/tr>\n \nOxidized anthracycline payloads induce antitumor immunogenic cell death and show linker-dependent tolerability when delivered as ADCs\n<\/p>\n<\/td>\n \n2013\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nChemistry \/ Drug Delivery\n<\/p>\n \nMon., April 17\n<\/p>\n \n9:00 a.m. – 12:30 p.m. ET\n<\/p>\n<\/td>\n \nJ. Hamilton\n<\/p>\n<\/td>\n<\/tr>\n \nReversible chemical modification of antibodies: A complementary approach to tuning Fc\u03b3R binding that maintains antitumor activity while mitigating peripheral immune activation\n<\/p>\n<\/td>\n \n2656\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nExperimental and Molecular Therapeutics \/ Antibody Technologies\n<\/p>\n \nMon., April 17\n<\/p>\n \n9:00 a.m. – 12:30 p.m. ET\n<\/p>\n<\/td>\n \nP. Moquist\n<\/p>\n<\/td>\n<\/tr>\n \nMMAE drives immunomodulatory changes in a preclinical xenograft model that are distinct from other clinical-stage ADC payloads\n<\/p>\n<\/td>\n \n4892\n<\/p>\n<\/td>\n \nPoster Presentation\n<\/p>\n \n\u00a0\n<\/p>\n \nExperimental and Molecular Therapeutics \/ Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment\n<\/p>\n \nTues., April 18\n<\/p>\n \n1:30 – 5:00 p.m. ET\n<\/p>\n<\/td>\n \nM. Ulrich\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n About Seagen<\/b><\/p>\n \nSeagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people\u2019s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit www.seagen.com<\/a> and follow @SeagenGlobal<\/a> on Twitter.\n<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nCertain statements made in this press release are forward-looking, such as those, among others, relating to the therapeutic potential of Seagen\u2019s products and product candidates, including their potential efficacy, safety and therapeutic uses, as well as the company\u2019s pipeline, technologies, collaborations and planned or ongoing clinical trials. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include without limitation the difficulty and uncertainty of pharmaceutical product development, including the risks that the company may experience delays in its clinical trials or otherwise experience failures or setbacks in its clinical development programs due to lack of efficacy, adverse events or other factors, and that adverse regulatory actions may occur. More information about the risks and uncertainties faced by Seagen is contained under the caption \u201cRisk Factors\u201d included in the company\u2019s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230314005811\/en\/<\/a><\/span><\/p>\n For Media For Investors KEYWORDS:<\/b> Florida Washington United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/p>\n
\n<\/i>
David Caouette
\n
(310) 430-3476
\n
dcaouette@seagen.com<\/a><\/p>\n
\n<\/i>
Douglas Maffei, Ph.D.
\n
(425) 527-4160
\n
dmaffei@seagen.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230314005811\/en\/828587\/3\/Seagen_Logo_RGB.jpg\"){kind=logo}
<\/td>\n<\/tr>\n